|
|
 |
TransPharma
Announces
Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in
Postmenopausal Women with Osteoporosis
September 1, 2009 – TransPharma Medical Ltd., a specialty
pharmaceutical company focused on the development and commercialization
of drug products utilizing a proprietary active transdermal drug
delivery technology, announced today the successful completion of the
Phase 2A trial of ViaDerm.
September 1, 2009
Read More
|
|
|
|
TransPharma
Announces
Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in
Postmenopausal Women with Osteoporosis
September 1, 2009 – TransPharma Medical Ltd., a specialty
pharmaceutical company focused on the development and commercialization
of drug products utilizing a proprietary active transdermal drug
delivery technology, announced today the successful completion of the
Phase 2A trial of ViaDerm.
September 1, 2009
Read More
|
|
TransPharma
Receives
European CE Mark Approval for its Transdermal Drug Delivery Device
TransPharma Medical Ltd., a specialty pharmaceutical company focused on
the development and commercialization of drug products utilizing a
proprietary active transdermal drug delivery technology, announced
today that it received European CE Mark approval for its ViaDerm, a
transdermal drug delivery device.
December 15, 2008
Read More
|
|
Frost
& Sullivan
Honours TransPharma Medical for its Innovative ViaDerm Drug Delivery
System
The 2008 Frost & Sullivan European Transdermal Drug Delivery
Product Innovation Award is conferred on Israel-based TransPharma
Medical Ltd. in recognition of its innovative ViaDerm drug delivery
system. The company’s two flagship drug product development programs -
ViaDerm hPTH (1-34) for the treatment of osteoporosis and ViaDerm-hGH
for the treatment of human growth hormone deficiency –both in phase 2
of clinical development.
August 2, 2008
Read More
|
|
Lilly
and TransPharma Medical
Announce Licensing and Development Agreement
Eli Lilly and Company (NYSE:LLY) and TransPharma Medical Ltd. today
announced that the two companies have entered into a licensing and
development agreement related to TransPharma's ViaDerm-hPTH (1-34)
product for the treatment of osteoporosis.
June 12, 2008
Read More
|
|
TransPharma
Medical Announces
Positive Results of Phase I Clinical Trials for Transdermal Delivery of
hPTH (1-34) for Osteoporosis Treatment
TransPharma Medical
Ltd., a specialty pharmaceutical company focused on the development and
commercialization of drug products utilizing a proprietary active
transdermal drug delivery technology, announced today promising results
of its phase I clinical trials demonstrating the safety and
pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the
treatment of osteoporosis.
July 9, 2007
Read More
|
|
TransPharma
Medical Receives Second
Milestone Payment from Teva Pharmaceutical Industries
TransPharma Medical
Ltd., a specialty pharmaceutical company focused on the development and
commercialization of drug products utilizing a proprietary active
transdermal drug delivery technology, announced today it has received
its second milestone payment from Teva Pharmaceutical Industries
June 11, 2007
Read
More
|
|
TransPharma
Medical Named
Winner of 2007 Red Herring 100 Europe Award
TransPharma Medical
Ltd., a specialty pharmaceutical company focused on the development and
commercialization of drug products utilizing a proprietary active
transdermal drug delivery technology, announced today that it has been
selected as a recipient of Red Herring 100 Europe.
March 21, 2007
Read
more
|
|
TransPharma
Medical Expands Board of Directors with Appointment of Industry Veteran
Larry Ellberger
TransPharma Medical Ltd., a
specialty pharmaceutical company focused on
the development and commercialization of drug products utilizing a
proprietary active transdermal drug delivery technology, announced
today the appointment of Larry Ellberger to the Company’s Board of
Directors.
March 12, 2007
Read more
|
|
TransPharma Medical
Completes $18 Million Series C Financing
Funding led by Argonaut with backing from Teva and current investors |
 |
| |
TransPharma Medical
Ltd., a specialty pharmaceutical company focused on the development and
commercialization of drug products utilizing a proprietary active
transdermal drug delivery technology, today announced that it has
secured $18 million in Series C financing.
July 24, 2006
Read more
|
|
Transpharma Medical Recieves First
Milestone Payment From TEVA Pharmaceuticals |
|
| |
TransPharma-Medical
Ltd., has received its first milestone payment from Teva
Pharmaceuticals.
May 1, 2006
Read more
|
|
Transpharma-Medical To Announce
Promising Results of Clinical Trials With its hPTH (1-34) - Transdermal
Delivery Product For Osteoporosis Treatment |
|
| |
TransPharma-Medical
Ltd., the Israeli-based specialty pharma company announces promising
results of first human clinical trials.
March 29, 2006
Read more
|
